ArticleScience advances2026
The MEK inhibitor trametinib incurs mitochondrial injury and induces innate immune responses in the mouse heart.
Abstract read
In one paragraph
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
35 authors.
Kelsey H Fisher-WellmanDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, NC, USA.ORCID 0000-0002-0300-829X
Richard D LutzeMcAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA.ORCID 0009-0007-3410-8182
Logan G KirklandMcAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA.
Ju Youn BeakMcAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA.
Mansi GoyalMcAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA.ORCID 0009-0002-5320-9142
Raghu NagalingamMcAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA.ORCID 0000-0003-1095-8303
Samantha M MorrisseyDepartment of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Peyton B SandroniMcAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA.
Wei HuangMcAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA.
Julian D BailonMcAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA.
Melissa A SchroderMcAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA.ORCID 0000-0002-8276-0315
Lars A AlbrechtMcAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA.ORCID 0009-0000-8661-545X
Ethelyn OfeiMcAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA.
Andrew L ChinMcAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA.
Thomas D GreenSection of Molecular Medicine, Department of Internal Medicine and Department of Vascular and Endovascular Surgery, Wake Forest University School of Medicine, Winston Salem, NC, USA.ORCID 0009-0008-5435-6957
Joseph M McClungSection of Molecular Medicine, Department of Internal Medicine and Department of Vascular and Endovascular Surgery, Wake Forest University School of Medicine, Winston Salem, NC, USA.
McLane M MontgomeryDepartment of Physiology, Brody School of Medicine, East Carolina University, Greenville, NC, USA.ORCID 0000-0002-8253-6858
James T HagenDepartment of Physiology, Brody School of Medicine, East Carolina University, Greenville, NC, USA.ORCID 0000-0002-0587-5370
Brett R ChrestDepartment of Physiology, Brody School of Medicine, East Carolina University, Greenville, NC, USA.ORCID 0009-0006-0936-7660
Edziu M FranczakDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, NC, USA.ORCID 0000-0002-0845-4002
Polina KrassovkaiaDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, NC, USA.ORCID 0000-0002-6271-3036
Raphael T ArulebaDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, NC, USA.ORCID 0000-0003-0879-344X
Jon S ZawistowskiDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.ORCID 0000-0001-8493-9813
Timothy J StuhlmillerDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Shawn M GomezDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.ORCID 0000-0002-8251-4552
Nanthip PrathumsapDepartment of Basic Medical Science, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Dusit, Bangkok 10300, Thailand.ORCID 0009-0003-0279-2451
Qing ZhangDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-6595-8995
Jing ZhangDepartment of Urology, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan, China.ORCID 0000-0001-6438-9113
Weiyi XuDepartment of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Lilei ZhangDepartment of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0001-6320-1318
Jeremy A MeierLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.ORCID 0000-0001-6321-5971
Lisa A CareyLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.ORCID 0000-0003-2388-4649
Jonathan C SchislerMcAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA.ORCID 0000-0001-7382-2783
Gary L JohnsonDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.ORCID 0000-0003-2867-0551
Brian C JensenMcAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA.ORCID 0000-0001-6430-8344
Funding
Tissue Procurement & PathologyP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LISA A CAREY, Gaorav P. Gupta · 1992 to 2026
$59.3MRe-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6MPILOT AND FEASIBILITY STUDIESP30DK034987 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBERT S. SANDLER · 1985 to 2026
$30.5MTissue Repository and Animal Models CoreP01CA171983 · NCI · UNIVERSITY OF VIRGINIA · PI FOX, TODD E · 2013 to 2024
$19.9MMetabolic mechanisms of cardioprotection through alpha-1A adrenergic receptor activationR01HL140067 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Brian C Jensen · 2018 to 2026
$4.2MDefining the role of mitochondrial injury in MEK inhibitor cardiotoxicityR01HL165294 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Brian C Jensen · 2023 to 2026
$2.1MMitochondrial bioenergetics and colorectal cancerR37CA278826 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Kelsey H Fisher-Wellman · 2024 to 2026
$1.6MNCATS NIH HHS UL1 TR002489NCI NIH HHS P01 CA171983NCI NIH HHS P50 CA058223NCI NIH HHS R37 CA278826NHLBI NIH HHS R01 HL140067NHLBI NIH HHS R01 HL165294NIDDK NIH HHS P30 DK034987
Abstract
Trametinib (Trm) is a highly selective mitogen-activated protein kinase kinase (MEK) inhibitor that potently and persistently abrogates extracellular signal-regulated kinase 1/2 activation. Trm initially was used to treat BRAF Val
Indexed as
Immunity, InnateMitochondria, HeartMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsPyridonesPyrimidinonesAnimalscGAS-STING Signaling PathwayDNA, MitochondrialHumansMaleMiceMyocytes, CardiacDNA, MitochondrialMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsPyridonesPyrimidinonestrametinib
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.